Don't expect GSK to spin off ViiV anytime soon

GlaxoSmithKline ($GSK) may have sequestered its HIV drugs and development in a joint venture with Pfizer ($PFE), ViiV Healthcare. But that doesn't mean the U.K.-based drugmaker intends to spin off the business. Not now, at least. "ViiV exists as a standalone company of which we are majority shareholders," GSK president of pharma R&D, Patrick Vallance, told Bloomberg. Handing over all its HIV work to ViiV, Valance said, has "provided a huge focus around the HIV space, and it's been an interesting lesson for GSK about how to get that sort of focus." Story


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.